Free Trial

Tourmaline Bio (TRML) Competitors

Tourmaline Bio logo
$19.68 -0.22 (-1.11%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$19.68 +0.00 (+0.03%)
As of 06/13/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TRML vs. IDYA, BLTE, SDGR, INDV, GLPG, APGE, BEAM, IMCR, TARS, and BHC

Should you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include IDEAYA Biosciences (IDYA), Belite Bio (BLTE), Schrödinger (SDGR), Indivior (INDV), Galapagos (GLPG), Apogee Therapeutics (APGE), Beam Therapeutics (BEAM), Immunocore (IMCR), Tarsus Pharmaceuticals (TARS), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry.

Tourmaline Bio vs. Its Competitors

IDEAYA Biosciences (NASDAQ:IDYA) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability.

IDEAYA Biosciences received 119 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 96.00% of users gave Tourmaline Bio an outperform vote while only 71.86% of users gave IDEAYA Biosciences an outperform vote.

CompanyUnderperformOutperform
IDEAYA BiosciencesOutperform Votes
143
71.86%
Underperform Votes
56
28.14%
Tourmaline BioOutperform Votes
24
96.00%
Underperform Votes
1
4.00%

Tourmaline Bio has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEAYA Biosciences$7M277.51-$274.48M-$3.59-6.18
Tourmaline BioN/AN/A-$42.12M-$3.21-6.13

Tourmaline Bio's return on equity of -20.97% beat IDEAYA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
IDEAYA BiosciencesN/A -26.74% -25.54%
Tourmaline Bio N/A -20.97%-20.56%

IDEAYA Biosciences has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500.

IDEAYA Biosciences presently has a consensus price target of $54.27, suggesting a potential upside of 144.69%. Tourmaline Bio has a consensus price target of $49.33, suggesting a potential upside of 150.68%. Given Tourmaline Bio's stronger consensus rating and higher probable upside, analysts clearly believe Tourmaline Bio is more favorable than IDEAYA Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEAYA Biosciences
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.93
Tourmaline Bio
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 2.5% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 13.0% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, IDEAYA Biosciences had 1 more articles in the media than Tourmaline Bio. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 6 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 1.49 beat IDEAYA Biosciences' score of 0.98 indicating that Tourmaline Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IDEAYA Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tourmaline Bio
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Tourmaline Bio beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks.

Get Tourmaline Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRML vs. The Competition

MetricTourmaline BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$505.48M$3.09B$5.57B$8.50B
Dividend YieldN/A1.56%5.27%4.17%
P/E Ratio-6.9832.6326.7519.65
Price / SalesN/A455.18403.98152.07
Price / CashN/A168.6838.2534.64
Price / Book1.953.366.964.59
Net Income-$42.12M-$72.35M$3.23B$248.23M
7 Day Performance2.13%0.36%-1.22%-1.07%
1 Month Performance26.80%16.10%6.34%2.59%
1 Year Performance16.04%-15.37%33.05%13.50%

Tourmaline Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRML
Tourmaline Bio
2.8478 of 5 stars
$19.68
-1.1%
$49.33
+150.7%
+16.0%$505.48MN/A-6.9844Analyst Revision
IDYA
IDEAYA Biosciences
3.8478 of 5 stars
$21.71
-0.1%
$54.27
+150.0%
-41.8%$1.90B$7M-6.5880Analyst Revision
Gap Down
BLTE
Belite Bio
2.6268 of 5 stars
$61.40
+2.9%
$96.67
+57.4%
+19.2%$1.90BN/A-55.3110Short Interest ↑
Analyst Revision
SDGR
Schrödinger
2.4804 of 5 stars
$25.47
+3.5%
$32.80
+28.8%
+3.9%$1.87B$230.49M-10.88790
INDV
Indivior
2.5698 of 5 stars
$13.43
-4.5%
$15.00
+11.7%
-16.0%$1.85B$1.17B-38.371,164Positive News
GLPG
Galapagos
0.2625 of 5 stars
$28.09
+1.3%
$25.33
-9.8%
+13.1%$1.85B$288.19M0.001,310Positive News
APGE
Apogee Therapeutics
2.3942 of 5 stars
$40.13
-2.1%
$94.60
+135.7%
+8.1%$1.85BN/A-16.5891Positive News
Gap Down
BEAM
Beam Therapeutics
3.0804 of 5 stars
$18.17
-2.2%
$48.75
+168.3%
-31.4%$1.83B$63.58M-10.32510Analyst Revision
Gap Down
IMCR
Immunocore
3.0551 of 5 stars
$36.07
-3.2%
$58.89
+63.3%
-9.8%$1.81B$333.58M-37.97320Positive News
Analyst Upgrade
Analyst Revision
High Trading Volume
TARS
Tarsus Pharmaceuticals
1.9151 of 5 stars
$43.11
-1.8%
$66.67
+54.6%
+32.0%$1.81B$233.67M-11.3150
BHC
Bausch Health Companies
3.9728 of 5 stars
$4.88
+2.5%
$7.42
+52.0%
-4.8%$1.81B$9.73B-40.6619,900News Coverage
Positive News
Insider Trade

Related Companies and Tools


This page (NASDAQ:TRML) was last updated on 6/15/2025 by MarketBeat.com Staff
From Our Partners